# EDGAR Filing Document

**Accession Number:** 0000896264
**File Stem:** 0000896264-26-000034
**Filing Date:** 2026-5
**Character Count:** 121590
**Document Hash:** 40a594ffa3f45154c9af0100c989c482
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000896264-26-000034.hdr.sgml**: 20260512

**ACCESSION NUMBER**: 0000896264-26-000034

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 61

**CONFORMED PERIOD OF REPORT**: 20260404

**FILED AS OF DATE**: 20260512

**DATE AS OF CHANGE**: 20260512

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** USANA HEALTH SCIENCES INC
- **CENTRAL INDEX KEY:** 0000896264
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 870500306
- **STATE OF INCORPORATION:** UT
- **FISCAL YEAR END:** 0103

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35024
- **FILM NUMBER:** 26969237

**BUSINESS ADDRESS:**
- **STREET 1:** 3838 WEST PARKWAY BLVD.
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84120-6336
- **BUSINESS PHONE:** 8019547100

**MAIL ADDRESS:**
- **STREET 1:** 3838 WEST PARKWAY BLVD.
- **STREET 2:** 3838 WEST PARKWAY BLVD.
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84120-6336

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** USANA INC
- **DATE OF NAME CHANGE:** 19930125

?xml version='1.0' encoding='ASCII'? usna-20260404

<u>[**Table of Contents**](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

______________________

**FORM 10-Q**

**(Mark One)**

⌧ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the quarterly period ended April 4, 2026**

or

□ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the transition period from ___________ to ____________**

**Commission file number: 001-35024**

______________________

**USANA HEALTH SCIENCES, INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Utah** | **87-0500306** |
| (State or other jurisdiction | (I.R.S. Employer |
| of incorporation or organization) | Identification No.) |

---

______________________

**3838 West Parkway Blvd., Salt Lake City, Utah 84120**

(Address of principal executive offices, including zip code)

______________________

**(801) 954-7100**

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock | USNA | New York Stock Exchange |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No □

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No □

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | □ | Accelerated filer | ⌧ |
| Non-accelerated filer | □ | Smaller reporting company | □ |
| | | Emerging growth company | □ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes □ No ⌧

As of May 8, 2026, there were 18,463,011 outstanding shares of the registrant's common stock, $0.001 par value.

Auditor Name: KPMG LLP Auditor Location: Salt Lake City, Utah Auditor Firm ID: 185

------

<u>[**Table of Contents**](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

**USANA HEALTH SCIENCES, INC.**

**FORM 10-Q**

**For the Quarterly Period Ended April 4, 2026**

**TABLE OF CONTENTS** 

---

| | | |
|:---|:---|:---|
| | | **Page** |
| <u>[Cautionary Note Regarding Forward-Looking Statements and Certain Risks](#i07b26d4eeded49c69f3a6bfc811b20be_10)</u> | <u>[Cautionary Note Regarding Forward-Looking Statements and Certain Risks](#i07b26d4eeded49c69f3a6bfc811b20be_10)</u> | <u>[1](#i07b26d4eeded49c69f3a6bfc811b20be_10)</u> |
| **<u>[PART I. FINANCIAL INFORMATION](#i07b26d4eeded49c69f3a6bfc811b20be_13)</u>** | **<u>[PART I. FINANCIAL INFORMATION](#i07b26d4eeded49c69f3a6bfc811b20be_13)</u>** | **<u>[PART I. FINANCIAL INFORMATION](#i07b26d4eeded49c69f3a6bfc811b20be_13)</u>** |
| <u>[Item 1](#i07b26d4eeded49c69f3a6bfc811b20be_16)</u> | <u>[Financial Statements (unaudited)](#i07b26d4eeded49c69f3a6bfc811b20be_16)</u> | <u>[4](#i07b26d4eeded49c69f3a6bfc811b20be_13)</u> |
|  | &nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Balance Sheets](#i07b26d4eeded49c69f3a6bfc811b20be_19)</u> | <u>[4](#i07b26d4eeded49c69f3a6bfc811b20be_19)</u> |
|  | &nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Comprehensive Income](#i07b26d4eeded49c69f3a6bfc811b20be_22)</u> | <u>[5](#i07b26d4eeded49c69f3a6bfc811b20be_22)</u> |
|  | &nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Stockholders' Equity](#i07b26d4eeded49c69f3a6bfc811b20be_25)</u> | <u>[6](#i07b26d4eeded49c69f3a6bfc811b20be_25)</u> |
|  | &nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Cash Flows](#i07b26d4eeded49c69f3a6bfc811b20be_28)</u> | <u>[7](#i07b26d4eeded49c69f3a6bfc811b20be_28)</u> |
|  | &nbsp;&nbsp;&nbsp;<u>[Notes to Condensed Consolidated Financial Statements](#i07b26d4eeded49c69f3a6bfc811b20be_31)</u> | <u>[8](#i07b26d4eeded49c69f3a6bfc811b20be_31)</u> - <u>[18](#i9cf91f111e314b3896f63d3075413f85_4-0-1-1-176628)</u> |
| <u>[Item 2](#i07b26d4eeded49c69f3a6bfc811b20be_76)</u> | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#i07b26d4eeded49c69f3a6bfc811b20be_76)</u> | <u>[19](#i07b26d4eeded49c69f3a6bfc811b20be_76)</u> - <u>[27](#i07b26d4eeded49c69f3a6bfc811b20be_103)</u> |
| <u>[Item 3](#i07b26d4eeded49c69f3a6bfc811b20be_103)</u> | <u>[Quantitative and Qualitative Disclosures About Market Risk](#i07b26d4eeded49c69f3a6bfc811b20be_103)</u> | <u>[27](#i07b26d4eeded49c69f3a6bfc811b20be_103)</u> |
| <u>[Item 4](#i07b26d4eeded49c69f3a6bfc811b20be_106)</u> | <u>[Controls and Procedures](#i07b26d4eeded49c69f3a6bfc811b20be_106)</u> | <u>[27](#i07b26d4eeded49c69f3a6bfc811b20be_106)</u> |
| **<u>[PART II. OTHER INFORMATION](#i07b26d4eeded49c69f3a6bfc811b20be_109)</u>** | **<u>[PART II. OTHER INFORMATION](#i07b26d4eeded49c69f3a6bfc811b20be_109)</u>** | **<u>[PART II. OTHER INFORMATION](#i07b26d4eeded49c69f3a6bfc811b20be_109)</u>** |
| <u>[Item 1](#i07b26d4eeded49c69f3a6bfc811b20be_112)</u> | <u>[Legal Proceedings](#i07b26d4eeded49c69f3a6bfc811b20be_112)</u> | <u>[29](#i07b26d4eeded49c69f3a6bfc811b20be_112)</u> |
| <u>[Item 1A](#i07b26d4eeded49c69f3a6bfc811b20be_115)</u> | <u>[Risk Factors](#i07b26d4eeded49c69f3a6bfc811b20be_115)</u> | <u>[29](#i07b26d4eeded49c69f3a6bfc811b20be_115)</u> |
| <u>[Item 2](#i07b26d4eeded49c69f3a6bfc811b20be_118)</u> | <u>[Unregistered Sales of Equity Securities and Use of Proceeds](#i07b26d4eeded49c69f3a6bfc811b20be_118)</u> | <u>[29](#i07b26d4eeded49c69f3a6bfc811b20be_118)</u> |
| <u>[Item 5](#i07b26d4eeded49c69f3a6bfc811b20be_124)</u> | <u>[Other Information](#i07b26d4eeded49c69f3a6bfc811b20be_124)</u> | <u>[29](#i07b26d4eeded49c69f3a6bfc811b20be_124)</u> |
| <u>[Item 6](#i07b26d4eeded49c69f3a6bfc811b20be_127)</u> | <u>[Exhibits](#i07b26d4eeded49c69f3a6bfc811b20be_127)</u> | <u>[30](#i07b26d4eeded49c69f3a6bfc811b20be_127)</u> |
| <u>[Signatures](#i07b26d4eeded49c69f3a6bfc811b20be_130)</u> |  | <u>[31](#i07b26d4eeded49c69f3a6bfc811b20be_130)</u> |

---

------

<u>[**Table of Contents**](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

**Cautionary Note Regarding Forward-Looking Statements and Certain Risks**

This report contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws, including any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new products; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. Forward-looking statements may include, but are not limited to, statements regarding future financial results, long-term value creation goals, focus and strategy, integration of acquisitions and performance expectations regarding such acquisitions, productivity, raw material prices and related costs, supply chain, asset impairment, litigation, sustainability and governance efforts, compliance with current or proposed international laws and regulations, the impact of COVID-19 or other pandemics, or geo-political relationships, trade policies, tariffs, tensions, conflicts or wars on our operations. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "seek," "believe," "project," "estimate," "target", "expect," "strategy," "potential", "future," "likely," "may," "should," "could", "will" and similar references to future periods, or the negative of these terms, or other similar expressions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely unduly on forward-looking statements.

Although we believe that the expectations reflected in our forward-looking statements are reasonable, actual results could differ materially from those we project or assume in our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and to inherent risks and uncertainties, such as those disclosed or incorporated by reference in our filings with the Securities and Exchange Commission ("SEC"). Any forward-looking statement made by us in this report is based only on information currently available to us and speaks only as of the date hereof. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, the occurrence of unanticipated events or otherwise. Among some of the important factors that could cause our actual results, performance and achievements to differ materially from estimates or projections contained in our forward-looking statements in this report are the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our dependence upon our Core Nutritional and direct sales business model to distribute our nutritional, foods and personal care products and the activities of our independent Brand Partners (whom we formerly referred to as "Associates") to grow our business; our core business is referred to in this report as both our Core Nutritional business and the direct sales business and has declined in net sales, net income and active Customers over the last few years;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The evolution of our consolidated business to an omni-channel health and wellness company and related dependence on our acquired direct-to-consumer businesses, Hiya Health Products, LLC ("Hiya") and Rise Bar Wellness, Inc. ("Rise"), to grow our business in channels outside of our Core Nutritional business including direct-to-consumer, retail, and online marketplaces;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our ability to invest in R&D, to innovate and produce new products, and to increase the cadence of releasing new products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Extensive regulation of our Core Nutritional business and uncertainties relating to the interpretation and enforcement of applicable laws and regulations governing direct selling and anti-pyramiding in the United States, China, and other markets where we have operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The operation of our Core Nutritional business in China through our subsidiary, BabyCare Holdings, Ltd. ("BabyCare"), including risks related to (i) operating in China in general, (ii) engaging in direct selling in China, (iii) BabyCare's business model in China, (iv) data privacy and security laws and regulations in China, and (v) changes in the Chinese economy, marketplace or consumer environment;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Export control and trade sanctions laws and regulations which could impair our ability to compete in international markets or subject us to liability if we violate those controls;

------

<u>[**Table of Contents**](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our Brand Partner Compensation Plan, or changes we may make to it, may be viewed negatively by some Brand Partners, could fail to achieve our desired objectives, and could have a negative impact on our Core Nutritional business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Product liability claims, litigation or other liability associated with our products or the manufacturing of our products by us or third parties;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Challenges associated with our planned expansion into new international markets, delays in commencement of sales or product offerings in such markets, delays in compliance with local marketing or other regulatory requirements, or changes in target markets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Macroeconomic conditions and other factors, including inflationary pressures, slower economic growth or recession, general conditions affecting consumer spending or discretionary income, or disruptions to our supply chain;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Hiya's growth strategy, including (i) their expansion into additional distribution channels and international markets, and (ii) ability to adapt to changes in the digital marketing environment to generate customer acquisition, including changes in social media advertising algorithms;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Rise's growth strategy, including their dependence on product orders from certain key retailers and the risk that future orders do not materialize or meet our forecasts;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Political events, natural disasters, pandemics, epidemics or other health crises including, and in addition to, COVID-19, or other events that may negatively affect economic conditions, consumer spending or consumer behavior;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Changes in the legal and regulatory environment including environmental, health and safety regulations, data security and privacy, and trade policies and tariffs, the impact of customs, duties, taxation, and transfer pricing regulations, as well as regulations governing distinctions between and our responsibilities to employees and independent contractors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Geopolitical tensions or conflicts, including impacts from the conflicts involving Russia and Ukraine; Israel and Palestine; and the United States, Israel and Iran; deterioration in foreign relations, as well as disputes or tensions among other countries around the world in general or among the United States, China and other countries;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Volatile fluctuation in the value of foreign currencies against the U.S. dollar;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Noncompliance by us or our Brand Partners with any data privacy or security laws or any security breach by us or a third-party involving the misappropriation, loss, destruction or other unauthorized use or disclosure of confidential information;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Shortages of raw materials, disruptions in the business of our contract manufacturers, significant price increases of key raw materials, and other disruptions to our supply chain;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our continued compliance with debt covenants in our credit facility agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Litigation, tax, and legal compliance risk and costs, especially if materially different from the amount we expect to incur or have accrued for, and any disruptions caused by the same;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Information technology system failures, data security breaches, data security and privacy compliance, network disruptions, and cybersecurity attacks;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Acquisition, divestiture, and investment-related risks, including risks associated with our acquisition of Hiya, Rise, or other past or future acquisitions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Human capital risks associated with our business, including if we are unable to attract or retain Brand Partner leaders to sell our products or if we lose key management personnel or employees in our Core Nutritional or direct-to-consumer businesses;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our ability to adequately protect and enforce our intellectual property and proprietary technology;

------

<u>[**Table of Contents**](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our ability to incorporate and utilize artificial intelligence technology effectively and compliantly; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Other risks and uncertainties, including those listed in the section titled "*Item 1A. Risk Factors*" in our fiscal year 2025 Annual Report on Form 10-K.

Unless otherwise indicated or otherwise required by the context, the terms "we," "our," "it," "its," "Company," and "USANA" refer to USANA Health Sciences, Inc. and its wholly owned subsidiaries, including Hiya and Rise.

------

<u>[**Table of Contents**](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

**PART I. FINANCIAL INFORMATION**

**Item 1. FINANCIAL STATEMENTS**

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(in thousands, except par value)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
| | **As of<br>April 4,<br>2026** | **As of<br>January 3, <br>2026** |
| **ASSETS** | | |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $162751 | $158380 |
| &nbsp;&nbsp;&nbsp;Trade accounts receivable (net of allowance of $141 and $137, respectively) | 9657 | 4285 |
| &nbsp;&nbsp;&nbsp;Inventories | 96358 | 102608 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 25467 | 23132 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 294233 | 288405 |
| Property and equipment, net | 94625 | 94383 |
| Goodwill | 138127 | 137962 |
| Intangible assets, net | 128901 | 133151 |
| Deferred tax assets | 25159 | 27209 |
| Other assets | 57921 | 61805 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $738966 | $742915 |
| **LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST, AND STOCKHOLDERS' EQUITY** |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $16230 | $17263 |
| &nbsp;&nbsp;&nbsp;Line of credit | 14000 | 14000 |
| &nbsp;&nbsp;&nbsp;Other current liabilities | 87009 | 97302 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 117239 | 128565 |
| Deferred tax liabilities | 5057 | 4892 |
| Other long-term liabilities | 21884 | 23186 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 144180 | 156643 |
| Redeemable noncontrolling interest | 51236 | 53168 |
| Stockholders' equity |  |  |
| &nbsp;&nbsp;&nbsp;Common stock, $0.001 par value; Authorized -- 50,000 shares, issued and outstanding 18,457 as of April 4, 2026 and 18,281 as of January 3, 2026 | 18 | 18 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 84733 | 83544 |
| &nbsp;&nbsp;&nbsp;Retained earnings | 473235 | 465720 |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive income (loss) | (14436) | (16178) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity attributable to USANA | 543550 | 533104 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities, redeemable noncontrolling interest, and stockholders' equity | $738966 | $742915 |

---

The accompanying notes are an integral part of these statements.

------

<u>[**Table of Contents**](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**

**(in thousands, except per share data)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
| | **Three months ended** | **Three months ended** |
| | **April 4,<br>2026** | **March 29,<br>2025** |
| Net sales | $250218 | $249539 |
| Cost of sales | 59436 | 52445 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 190782 | 197094 |
| Operating expenses: |  |  |
| &nbsp;&nbsp;&nbsp;Brand Partner incentives | 88654 | 89985 |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative | 88254 | 91438 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 176908 | 181423 |
| Earnings from operations | 13874 | 15671 |
| Other income (expense): |  |  |
| &nbsp;&nbsp;&nbsp;Interest income | 437 | 723 |
| &nbsp;&nbsp;&nbsp;Interest expense | (240) | (411) |
| &nbsp;&nbsp;&nbsp;Other, net | 1394 | 756 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income (expense), net | 1591 | 1068 |
| Earnings before income taxes | 15465 | 16739 |
| Income taxes | 8506 | 7449 |
| &nbsp;&nbsp;Net earnings | 6959 | 9290 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net (loss) earnings attributable to redeemable noncontrolling interest | (556) | (112) |
| &nbsp;&nbsp;Net earnings attributable to USANA | $7515 | $9402 |
| Earnings per common share attributable to USANA |  |  |
| &nbsp;&nbsp;Basic | $0.41 | $0.49 |
| &nbsp;&nbsp;Diluted | $0.41 | $0.49 |
| Weighted average common shares outstanding |  |  |
| &nbsp;&nbsp;&nbsp;Basic | 18398 | 19049 |
| &nbsp;&nbsp;&nbsp;Diluted | 18411 | 19085 |
| Comprehensive income (loss): |  |  |
| Net earnings | $6959 | $9290 |
| Other comprehensive income (loss), net of tax: |  |  |
| &nbsp;&nbsp;&nbsp;Foreign currency translation adjustment | 1878 | 125 |
| &nbsp;&nbsp;&nbsp;Tax (expense) benefit related to foreign currency translation adjustment | (136) | (207) |
| Other comprehensive income (loss), net of tax | 1742 | (82) |
| Comprehensive income (loss) | 8701 | 9208 |
| &nbsp;&nbsp;&nbsp;Comprehensive (loss) income attributable to redeemable noncontrolling interest | (556) | (112) |
| Comprehensive income (loss) attributable to USANA | $9257 | $9320 |

---

The accompanying notes are an integral part of these statements.

------

<u>[**Table of Contents**](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**

**(in thousands)**

**(unaudited)**

For the three months ended March 29, 2025

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Common stock** | **Common stock** | **Additional<br>paid-in<br>capital** | **Retained<br>earnings** | **Accumulated<br>other<br>comprehensive<br>income (loss)** | **Total stockholders' equity attributable to USANA** |
| | **Shares** | **Value** | **Additional<br>paid-in<br>capital** | **Retained<br>earnings** | **Accumulated<br>other<br>comprehensive<br>income (loss)** | **Total stockholders' equity attributable to USANA** |
| Balance at December 28, 2024 | 19064 | $19 | $75816 | $478944 | $(22670) | $532109 |
| Net earnings attributable to USANA |  |  |  | 9402 |  | 9402 |
| Other comprehensive income (loss), net of tax |  |  |  |  | (82) | (82) |
| Equity-based compensation expense |  |  | 2880 |  |  | 2880 |
| Common stock repurchased and retired | (399) |  | (1662) | (10718) |  | (12380) |
| Common stock issued under equity award plans | 121 |  |  |  |  |  |
| Tax withholding for net-share settled equity awards |  |  | (2167) |  |  | (2167) |
| Balance at March 29, 2025 | 18786 | $19 | $74867 | $477628 | $(22752) | $529762 |

---

For the three months ended April 4, 2026

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Common stock** | **Common stock** | **Additional<br>paid-in<br>capital** | **Retained<br>earnings** | **Accumulated<br>other<br>comprehensive<br>income (loss)** | **Total stockholders' equity attributable to USANA** |
| | **Shares** | **Value** | **Additional<br>paid-in<br>capital** | **Retained<br>earnings** | **Accumulated<br>other<br>comprehensive<br>income (loss)** | **Total stockholders' equity attributable to USANA** |
| Balance at January 3, 2026 | 18281 | $18 | $83544 | $465720 | $(16178) | $533104 |
| Net earnings attributable to USANA |  |  |  | 7515 |  | 7515 |
| Other comprehensive income (loss), net of tax |  |  |  |  | 1742 | 1742 |
| Equity-based compensation expense |  |  | 3454 |  |  | 3454 |
| Common stock issued under equity award plans | 176 |  |  |  |  |  |
| Tax withholding for net-share settled equity awards |  |  | (2265) |  |  | (2265) |
| Balance at April 4, 2026 | 18457 | $18 | $84733 | $473235 | $(14436) | $543550 |

---

The accompanying notes are an integral part of these statements.

------

<u>[**Table of Contents**](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(in thousands)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
| | **Three months ended** | **Three months ended** |
| | **April 4,<br>2026** | **March 29,<br>2025** |
| Cash flows from operating activities |  |  |
| &nbsp;&nbsp;&nbsp;Net earnings | $6959 | $9290 |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net earnings to net cash provided by (used in) operating activities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 8277 | 8339 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Right-of-use asset reduction | 1512 | 1906 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on sale of property and equipment | 13 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation expense | 3454 | 2880 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | 2108 | 1355 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory write-down | 1299 | 1211 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trade accounts receivable | (5367) | 1004 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | 6597 | (4921) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | (1689) | (1256) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | (1459) | 1975 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | (11945) | (6301) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) operating activities | 9759 | 15482 |
| Cash flows from investing activities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments for net investment hedge |  | (1072) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sale of property and equipment | 48 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of property and equipment | (2645) | (2803) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) investing activities | (2597) | (3875) |
| Cash flows from financing activities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Repurchase of common stock |  | (12300) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Borrowings on line of credit | 4000 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments on line of credit | (4000) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments related to tax withholding for net-share settled equity awards | (2265) | (2167) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Distributions to redeemable noncontrolling interest | (1376) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) financing activities | (3641) | (14467) |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 896 | 719 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net increase (decrease) in cash, cash equivalents, and restricted cash | 4417 | (2141) |
| Cash, cash equivalents, and restricted cash at beginning of period | 161240 | 184508 |
| Cash, cash equivalents, and restricted cash at end of period | $165657 | $182367 |
| Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets |  |  |
| Cash and cash equivalents | $162751 | $179613 |
| Restricted cash included in other assets | 2906 | 2754 |
| Total cash, cash equivalents, and restricted cash | $165657 | $182367 |
| Supplemental disclosures of cash flow information |  |  |
| &nbsp;&nbsp;&nbsp;Cash paid during the period for: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest | $242 | $52 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes | 9111 | 7767 |
| &nbsp;&nbsp;&nbsp;Cash received during the period for: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax refund |  | 38 |
| &nbsp;&nbsp;&nbsp;Non-cash investing and financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Right-of-use assets obtained in exchange for lease obligations | 214 | 3938 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued purchases of property and equipment | 419 | 31 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued excise tax for repurchase of common stock |  | 80 |

---

The accompanying notes are an integral part of these statements.

------

<u>[**Table of Contents**](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(in thousands, except per share data)**

**(unaudited)**

**NOTE A – ORGANIZATION, CONSOLIDATION, AND BASIS OF PRESENTATION**

USANA Health Sciences, Inc. and subsidiaries ("the Company") is a global nutritional, personal health and wellness company that develops and manufactures high quality, science-based nutritional and personal care products. For financial reporting purposes, the Company categorizes its operations into three reportable segments: Core Nutritional, Hiya, and Rise. Effective January 4, 2026, the Company reorganized its reportable segments to reflect changes in how its chief operating decision maker (CODM) evaluates the Company's business performance and allocates resources. All prior period segment information has been recast to conform to the current period presentation.

Core Nutritional is the Company's primary business with approximately 82% of consolidated net sales year to date 2026. It is grouped and presented in two geographic regions:

*Asia Pacific*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Asia Pacific is organized into three sub-regions: Greater China, Southeast Asia Pacific, and North Asia. Markets included in each of these sub-regions are as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)Greater China – Hong Kong, Taiwan, and China. The Company's business in China is conducted by BabyCare, the Company's wholly owned subsidiary.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)Southeast Asia Pacific – Australia, New Zealand, Singapore, Malaysia, the Philippines, Thailand, Indonesia and India.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)North Asia – Japan and South Korea.

*Americas and Europe*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Americas and Europe – United States, Canada, Mexico, Colombia, and Europe (the United Kingdom, France, Germany, Spain, Italy, Romania, Belgium, and the Netherlands).

In 2024, the Company entered into a merger agreement with Hiya Health Products, LLC ("Hiya"), a leading direct-to-consumer provider of high-quality children's health and wellness products, by which the Company acquired a 78.85% controlling ownership interest. Hiya operates and sells products in the United States, and during the first quarter of 2026 expanded into Canada and the United Kingdom. In 2022, the Company acquired Rise Bar Wellness, Inc. ("Rise") and has expanded Rise's product offering, distribution channel, and customer base over the last three years. Rise operates and sells products in the United States and Canada. Consequently, through the Company's Core Nutritional business, Hiya and Rise, we now operate and sell products through an omni-channel platform, which includes direct selling, direct-to-consumer, third-party marketplace (i.e. Amazon), and retail channels.

The condensed consolidated balance sheet as of January 3, 2026, derived from audited consolidated financial statements, and the unaudited interim condensed consolidated financial information of the Company have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X promulgated by the SEC. Accordingly, certain information and disclosures that are normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") have been condensed or omitted pursuant to such rules and regulations. The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. In the opinion of the Company's management, the accompanying unaudited interim condensed consolidated financial information contains all adjustments, consisting only of normal recurring adjustments, that are necessary to state fairly the Company's financial position as of April 4, 2026, and results of operations and cash flows for the three months ended April 4, 2026 and March 29, 2025.

------

<u>[**Table of Contents**](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(in thousands, except per share data)**

**(unaudited)**

The interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto that are included in the Company's Annual Report on Form 10-K for the year ended January 3, 2026. The results of operations for the three months ended April 4, 2026, are not necessarily indicative of the results that may be expected for the fiscal year ending January 2, 2027.

Certain reclassifications have been made to prior period amounts to conform to current period presentation. These reclassifications had no effect on the reported results of operations. These reclassifications relate to disaggregation of Trade accounts receivable, net, that were previously included within "Prepaid expenses and other current assets" and "Prepaid expenses and other assets" line items of the condensed consolidated balance sheets and the condensed consolidated statements of cash flows, respectively.

<u>Fiscal Year</u>

The Core Nutritional and Rise segments operate on a 52/53-week year, ending on the Saturday closest to December 31. The Hiya segment currently operates on a calendar year end basis ending on December 31.

<u>Recent Accounting Pronouncements</u>

*Issued Accounting Pronouncements Not Yet Adopted*

In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-04): Expense Disaggregation Disclosures. The standard is intended to provide investors with more decision-useful information about a public business entity's expenses by improving disclosures on income statement expenses through disclosure of disaggregated information about specific natural expense categories underlying certain relevant income statement expense line items that include one or more of five natural expense categories. ASU 2024-03 is effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that adoption of the standard will have on its consolidated financial statements.

In September 2025, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. The standard is intended to modernize old internal-use software guidance written in 1998 to adapt to the agile (i.e. iterative and flexible) basis predominantly used to develop software today. ASU 2025-06 is effective for annual and interim reporting periods beginning after December 15, 2027. Early adoption is permitted as of the beginning of an annual reporting period. The guidance requires adoption on either a prospective, retrospective, or modified prospective basis. The Company is currently evaluating the impact that adoption of the standard will have on its consolidated financial statements.

No other recent accounting pronouncements had, or are expected to have, a material impact on the Company's consolidated financial statements.

**NOTE B – FAIR VALUE MEASURES**

The Company measures, at fair value, certain of its financial and non-financial assets and liabilities by using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price, based on the highest and best use of the asset or liability. The levels of the fair value hierarchy are:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 1 inputs are quoted market prices in active markets for identical assets or liabilities that are accessible at the measurement date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 2 inputs are from other than quoted market prices included in Level 1 that are observable for the asset or liability, either directly or indirectly.

------

<u>[**Table of Contents**](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(in thousands, except per share data)**

**(unaudited)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 3 inputs are unobservable and are used to measure fair value in situations where there is little, if any, market activity for the asset or liability at the measurement date.

As of April 4, 2026 and January 3, 2026, the following financial assets and liabilities were measured at fair value on a recurring basis using the type of inputs shown:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **April 4,<br>2026** | **Fair value measurements using** | **Fair value measurements using** | **Fair value measurements using** |
| | **April 4,<br>2026** | **Inputs** | **Inputs** | **Inputs** |
| | **April 4,<br>2026** | **Level 1** | **Level 2** | **Level 3** |
| Money market funds included in cash equivalents | $98054 | $98054 | $— | $— |
| Net investment hedge included in other current liabilities | (344) |  | (344) |  |
| Deferred compensation liabilities included in other long-term liabilities | (5677) |  | (5677) |  |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **January 3,<br>2026** | **Fair value measurements using** | **Fair value measurements using** | **Fair value measurements using** |
| | **January 3,<br>2026** | **Inputs** | **Inputs** | **Inputs** |
| | **January 3,<br>2026** | **Level 1** | **Level 2** | **Level 3** |
| Money market funds included in cash equivalents | $87851 | $87851 | $— | $— |
| Foreign currency contracts included in other current liabilities | (26) |  | (26) |  |
| Deferred compensation liabilities included in other long-term liabilities | (6024) |  | (6024) |  |

---

There were no transfers of financial assets or liabilities between levels of the fair value hierarchy for the periods indicated.

The majority of the Company's non-financial assets, which include long-lived assets, are not required to be carried at fair value on a recurring basis. However, if an impairment charge is required, a non-financial asset would be written down to fair value. As of April 4, 2026, none of the Company's non-financial assets were measured at fair value. As of January 3, 2026, the fair value of the Buy-Sell reporting unit was estimated using an income approach and a market approach (level 3 measurement), which resulted in an impairment of goodwill in the reporting unit.

As of April 4, 2026 and January 3, 2026, the Company's financial instruments include cash equivalents, restricted cash, accounts receivable, and line of credit. The recorded values of cash equivalents, restricted cash, and accounts receivable approximate their fair values based on their short-term nature.

**NOTE C – INVENTORIES**

Inventories consist of the following:

---

| | | |
|:---|:---|:---|
| | **April 4,<br>2026** | **January 3,<br>2026** |
| Raw materials | $34013 | $31732 |
| Work in progress | 5214 | 5003 |
| Finished goods | 57131 | 65873 |
| Inventories | $96358 | $102608 |
| Noncurrent inventories | $3029 | $4799 |

---

As of April 4, 2026, noncurrent inventories consisted of $2,312 of raw materials and $717 of finished goods inventory. As of January 3, 2026, noncurrent inventories consisted of $3,928 of raw materials and $871 of finished goods inventory. Noncurrent inventories are included in the "Other assets" line item on the Company's condensed consolidated

------

<u>[**Table of Contents**](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(in thousands, except per share data)**

**(unaudited)**

balance sheets. Noncurrent inventory is anticipated to be consumed beyond the Company's normal operating cycle, but prior to obsolescence.

**NOTE D – INVESTMENT IN EQUITY SECURITIES**

As of April 4, 2026 and January 3, 2026, the carrying amount of equity securities without readily determinable fair values was $20,000 and is included in the "Other assets" line item on the Company's condensed consolidated balance sheets. The investment was made with the objective of generating long-term total return through capital appreciation, and, where applicable, dividend income.

During the three months ended April 4, 2026 and March 29, 2025, no observable price changes occurred and no adjustment to the carrying value of the securities was recorded. Additionally, no impairment of securities was recorded for the three months ended April 4, 2026, and March 29, 2025.

**NOTE E – REVENUE AND CONTRACT LIABILITIES**

Revenue is recognized when, or as, control of a promised product or service transfers to a customer, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for transferring those products or services. A majority of the Company's Core Nutritional sales are for products sold at a point in time and shipped to customers, for which control is transferred as goods are delivered to the third-party carrier for shipment. The Company receives payment, primarily via credit card, for the sale of products at the time customers place orders and payment is required prior to shipment.

Other revenue includes fees, which are paid by the customer at the beginning of the service period, for access to online customer service applications and annual account renewal fees for Brand Partners, for which control is transferred over time as services are delivered and are recognized as revenue on a straight-line basis over the term of the respective contracts.

The following table presents other revenue, included in Net sales in the condensed consolidated statements of comprehensive income, for the periods indicated:

---

| | | |
|:---|:---|:---|
| | **Three months ended** | **Three months ended** |
| | **April 4,<br>2026** | **March 29,<br>2025** |
| Other revenue | $482 | $498 |

---

Hiya's revenue is generated primarily from e-commerce/direct to consumer sales, with expansion into retail in the first quarter of 2026. Revenue from online product sales is recognized at the point in time when control of the promised good is transferred to the third-party shipping carrier. The Company receives payments, primarily via credit card and PayPal, for the sale of products at the time customers place orders and subsequent subscription orders, and payment is required prior to shipment. There are no extended payment terms offered to consumers. To encourage customers to purchase its products, the Company provides incentive offers on initial orders. These offers, when accepted by customers, are treated as a reduction to the transaction price.

Rise's revenue is generated primarily from sales to large national retailers and club retailers, with revenue recognized at the point in time when control of the promised good is transferred to the third-party shipping carrier. The transaction price may include variable consideration arising from trade promotional programs, discounts, spoilage, and other retailer deductions. The Company estimates variable consideration using the expected value method based on historical experience, contractual terms, and current market conditions. Variable consideration is recognized as a reduction of net revenue in the period the related sales are recorded.

------

<u>[**Table of Contents**](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(in thousands, except per share data)**

**(unaudited)**

As of April 4, 2026, two of the Company's customers each accounted for more than 10% of trade accounts receivable, representing approximately 46% and 47% of total trade accounts receivable, respectively. As of January 3, 2026, no customer accounted for 10% or more of trade accounts receivable.

Contract liabilities, which are recorded within the "Other current liabilities" line item in the Company's condensed consolidated balance sheets, primarily relate to deferred revenue for product sales for customer payments received in advance of shipment, for outstanding material rights under the initial order program, and for services where control is transferred over time as services are delivered. The Company does not recognize assets associated with costs to obtain or fulfill a contract with a customer.

Disaggregation of revenue by geographic region and major product line is included in <u>[Note J](#i07b26d4eeded49c69f3a6bfc811b20be_67)</u> – Segment Information.

The following table provides information about contract liabilities from contracts with customers, including significant changes in the contract liabilities balances during the period:

---

| | | |
|:---|:---|:---|
| | **April 4,<br>2026** | **January 3,<br>2026** |
| Contract liabilities, included in other current liabilities, at beginning of period | $10640 | $12050 |
| Increase due to deferral of revenue at end of period | 8202 | 10640 |
| Decrease due to beginning contract liabilities recognized as revenue | (8523) | (12050) |
| Contract liabilities, included in other current liabilities, at end of period | $10319 | $10640 |

---

**NOTE F – LINE OF CREDIT**

On June 27, 2025, the Company as borrower, and certain of its material subsidiaries as guarantors, entered into a Third Amended and Restated Credit Agreement (the "Credit Agreement") with Bank of America, N.A. ("Bank of America"), as Administrative Agent, Swingline Lender and Letter of Credit Issuer, and the other lenders party thereto.

The Credit Agreement provides for a revolving credit limit for loans to the Company of up to $75,000 (the "Credit Facility"). In addition, at the option of the Company, and subject to certain conditions, the Company may request to increase the aggregate commitment under the Credit Facility by up to $200,000.

There was $14,000 of outstanding debt balance on the Credit Facility as of April 4, 2026 and January 3, 2026. The obligations of the Company under the Credit Agreement are secured by the pledge of capital stock of subsidiaries of the Company, pursuant to a Security and Pledge Agreement.

Interest on revolving borrowings under the Credit Facility is computed using the Secured Overnight Financing Rate ("SOFR") or the base rate, which is based on the Federal Funds Rate, the Bank of America Prime Rate, or SOFR, adjusted by features specified in the Credit Agreement. The covenants require the Company's rolling four-quarter consolidated earnings before interest, taxes, depreciation and amortization ("EBITDA") (as defined in the Credit Agreement) to be equal to or greater than $80,000 for the period of four prior fiscal quarters ending on each of June 28, 2025, September 27, 2025, January 3, 2026, April 4, 2026, and July 4, 2026, and $100,000 for each fiscal quarter ending thereafter. The covenants also require the Company's ratio of consolidated funded debt to consolidated EBITDA to be equal to or less than 2.0 to 1.0 at the end of each quarter. The Credit Agreement does not include any restrictions on the payment of cash dividends or share repurchases by the Company. Consolidated EBITDA and consolidated funded debt are non-GAAP terms. The Company will be required to pay any balance on this Credit Facility in full at the time of maturity in June 2030.

The Company maintains local lines of credit across different markets to secure sufficient working capital. As of April 4, 2026 and January 3, 2026, there was no balance on the local lines of credit.

------

<u>[**Table of Contents**](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(in thousands, except per share data)**

**(unaudited)**

**NOTE G – CONTINGENCIES**

The Company is involved in various lawsuits, claims, and other legal matters from time to time that arise in the ordinary course of conducting business, including matters involving its products, intellectual property, supplier relationships, distributors, competitor relationships, employees and other matters. The Company records a liability when a particular contingency is probable and estimable. The Company faces contingencies that are reasonably possible to occur; however, they cannot currently be estimated. While complete assurance cannot be given as to the outcome of these proceedings, management does not currently believe that any of these matters, individually or in the aggregate, will have a material adverse effect on the Company's financial condition, liquidity or results of operations. It is reasonably possible that a change in the contingencies could result in a change in the amount recorded by the Company in the future.

**NOTE H – DERIVATIVE FINANCIAL INSTRUMENTS**

The Company's risk management strategy includes the select use of derivative instruments to reduce the effects of volatility in foreign currency exchange exposure on operating results and cash flows. In accordance with the Company's risk management policies, the Company does not hold or issue derivative instruments for trading or speculative purposes. The Company recognizes all derivative instruments as either assets or liabilities in the condensed consolidated balance sheets at their respective fair values. When the Company becomes a party to a derivative instrument and intends to apply hedge accounting, the Company formally documents the hedge relationship and the risk management objective for undertaking the hedge, the nature of risk being hedged, and the hedged transaction, which includes designating the instrument for financial reporting purposes as a fair value hedge, a cash flow hedge, or a net investment hedge. The Company also documents how the hedging instrument's effectiveness in offsetting the hedged risk will be assessed prospectively and retrospectively, and a description of the method used to measure ineffectiveness.

The Company periodically uses derivative instruments to hedge the foreign currency exposure of its net investment in foreign subsidiaries into U.S. dollars. Initially, the Company records derivative assets on a gross basis in its condensed consolidated balance sheets. Subsequently the fair value of derivatives is measured for each reporting period. The effective portion of gains and losses attributable to these net investment hedges is recorded to foreign currency translation adjustment ("FCTA") within accumulated other comprehensive income (loss) ("AOCI") to offset the change in the carrying value of the net investment being hedged and will subsequently be reclassified to net earnings in the period in which the investment in the subsidiary is either sold or substantially liquidated.

During the three months ended April 4, 2026, the Company entered into a forward foreign currency contract designated as a net investment hedge with a notional amount of $61,766. During the three months ended March 29, 2025, the Company entered into a European option designated as a net investment hedge with a notional amount of $70,062.

For the three months ended April 4, 2026 and March 29, 2025, the Company had unrealized losses of $344 and $853, respectively, related to its net investment hedges. These amounts were recorded in FCTA within AOCI. The Company assessed hedge effectiveness using the forward rate method and determined that the hedging instruments were highly effective.

**NOTE I – COMMON STOCK AND EARNINGS PER SHARE**

Basic earnings per share ("EPS") is based on the weighted-average number of shares outstanding for each period. Shares that have been repurchased and retired during the periods specified below have been included in the calculation of the number of weighted-average shares that are outstanding for the calculation of basic EPS based on the time they were outstanding in any period. Diluted EPS is based on shares that are outstanding (computed under basic EPS) and on potentially dilutive shares. Shares that are included in the diluted EPS calculations under the treasury stock method include equity awards that are in-the-money but have not yet been exercised.

------

<u>[**Table of Contents**](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(in thousands, except per share data)**

**(unaudited)**

The following is a reconciliation of the numerator and denominator used to calculate basic EPS and diluted EPS for the periods indicated:

---

| | | |
|:---|:---|:---|
| | **Three months ended** | **Three months ended** |
| | **April 4,<br>2026** | **March 29,<br>2025** |
| Net (loss) earnings attributable to USANA | $7515 | $9402 |
| Weighted average common shares outstanding - basic | 18398 | 19049 |
| Dilutive effect of in-the-money equity awards | 13 | 36 |
| Weighted average common shares outstanding - diluted | 18411 | 19085 |
| (Loss) earnings per common share from net (loss) earnings attributable to USANA: |  |  |
| &nbsp;&nbsp;Basic | $0.41 | $0.49 |
| &nbsp;&nbsp;Diluted | $0.41 | $0.49 |
| Equity awards excluded as the impact was anti-dilutive | 998 | 465 |

---

Under the Company's share repurchase plan, there were no share repurchases during the three months ended April 4, 2026. During the three months ended March 29, 2025, the Company repurchased and retired 399 shares for $12,380, inclusive of accrued excise tax of $80.

The excess of the repurchase price over par value is allocated between additional paid-in capital and retained earnings on a pro-rata basis. The purchase of shares under this plan reduces the number of shares outstanding in the above calculations.

As of April 4, 2026, the remaining authorized repurchase amount under the stock repurchase plan was $33,965, inclusive of accrued excise tax. There is no expiration date on the remaining approved repurchase amount and no requirement for future share repurchases.

**NOTE J – SEGMENT INFORMATION**

The Company primarily operates as a global nutrition, personal health and wellness company that develops and manufactures high quality, science-based nutritional, and personal care products. As of the Company's 2025 fiscal year ended January 3, 2026, the Company had two reportable segments: Core Nutritional and Hiya. Additionally, the Company had operating segments that were not material and included as a component of an other category. Effective January 4, 2026, the Company reorganized its reportable segments to three - Core Nutritional, Hiya, and Rise, reflecting the changes in how its chief operating decision maker ("CODM") evaluates the Company's business performance and allocates resources. Additionally, operations of Oola Global, LLC, which was previously included in the other category, were merged into the Core Nutritional segment. All prior period segment information has been recast to conform to the current period presentation.

Management identifies segments based upon the Company's organizational and management reporting structure. The Core Nutritional reportable segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a primary focus on promoting long-term health and wellness in various geographic markets worldwide that are distributed through the Core Nutritional channel. The Hiya reportable segment is a leading provider of high-quality children's health and wellness products in the U.S. that are distributed primarily through the direct-to-consumer channel, with recent expansion into retail sales. The Rise reportable segment manufactures and sells high-quality protein bars, powdered protein drinks, and ready-to-drink ("RTD") liquid protein drinks that are formulated to help customers achieve their health goals through clean and simple ingredients. Their products are distributed primarily through sales to large national retailers and club retailers, as well as through the direct-to-consumer channel.

------

<u>[**Table of Contents**](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(in thousands, except per share data)**

**(unaudited)**

The operating segments primarily reflect the Company's sales channels and represent the way the CODM evaluates the Company's business performance and allocates resources. The CODM is the Company's Chief Executive Officer. The CODM evaluates the performance of each segment based on segment earnings from operations in order to determine how to allocate the Company's resources across its operating segments, including allocating capital and personnel. Transactions between reportable segments are accounted for at cost plus a negotiated mark-up. Intersegment revenues and expenses are eliminated in consolidation and are not included in the Company's consolidated results. The negotiated mark-up is intended to approximate the return that would be expected in an arm's-length transaction and is reviewed periodically by management to ensure it remains commercially reasonable. The CODM does not evaluate operating segments using asset information, accordingly, the Company does not report asset information by segment.

In accordance with FASB Accounting Standards Codification ("ASC") 280, Segment Reporting, the Company has recast prior-period segment information to conform to the current-year presentation. The recast affects the presentation of segment financial information for the periods shown below, but there was no impact on the Company's condensed consolidated financial statements.

Summarized financial information for the Company's reportable segments is shown in the following tables, including significant segment expenses that are regularly reviewed by the CODM.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended<br>April 4, 2026** | **Three months ended<br>April 4, 2026** | **Three months ended<br>April 4, 2026** | **Three months ended<br>April 4, 2026** |
| | **Core Nutritional** | **Hiya** | **Rise** | **Total** |
| Net sales <sup>(1)</sup> | $204399 | $32150 | $13669 | $250218 |
| Less: |  |  |  |  |
| &nbsp;&nbsp;Cost of sales | 36749 | 9983 | 12704 | 59436 |
| &nbsp;&nbsp;Brand Partner incentives | 88654 |  |  | 88654 |
| &nbsp;&nbsp;Selling, general and administrative <sup>(2)</sup> | 60747 | 24771 | 2736 | 88254 |
| Segment earnings (loss) from operations | $18249 | $(2604) | $(1771) | $13874 |
| **Reconciliation of segment earnings from operations** |  |  |  |  |
| Interest income |  |  |  | 437 |
| Interest expense |  |  |  | (240) |
| Other, net |  |  |  | 1394 |
| &nbsp;&nbsp;Earnings before income taxes |  |  |  | $15465 |

---

**______________________________**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup>The Core Nutritional segment excludes $928 and $13,026 of intersegment net sales for Hiya and Rise, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(2)</sup>Includes amortization of acquired intangible assets of $4,455 and $211 for the Hiya and Rise segments, respectively.

------

<u>[**Table of Contents**](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(in thousands, except per share data)**

**(unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended<br>March 29, 2025** | **Three months ended<br>March 29, 2025** | **Three months ended<br>March 29, 2025** | **Three months ended<br>March 29, 2025** |
| | **Core Nutritional** | **Hiya** | **Rise** | **Total** |
| Net sales <sup>(1)</sup> | $210824 | $37089 | $1626 | $249539 |
| Less: |  |  |  |  |
| &nbsp;&nbsp;Cost of sales | 37279 | 14107 | 1059 | 52445 |
| &nbsp;&nbsp;Brand Partner incentives | 89985 |  |  | 89985 |
| &nbsp;&nbsp;Selling, general and administrative <sup>(2)</sup> | 66637 | 23513 | 1288 | 91438 |
| Segment earnings (loss) from operations | $16923 | $(531) | $(721) | $15671 |
| **Reconciliation of segment earnings from operations** |  |  |  |  |
| Interest income |  |  |  | 723 |
| Interest expense |  |  |  | (411) |
| Other, net |  |  |  | 756 |
| &nbsp;&nbsp;Earnings before income taxes |  |  |  | $16739 |

---

**______________________________**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup>The Core Nutritional segment excludes $764 of intersegment net sales to Rise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(2)</sup>Includes amortization of acquired intangible assets of $95, $4,455, and $211, for the Core Nutritional, Hiya, and Rise segments, respectively.

---

| | | |
|:---|:---|:---|
| | **Three months ended** | **Three months ended** |
| | **April 4,<br>2026** | **March 29,<br>2025** |
| Depreciation and amortization: |  |  |
| &nbsp;&nbsp;&nbsp;Core Nutritional | $3598 | $3645 |
| &nbsp;&nbsp;&nbsp;Hiya | 4468 | 4483 |
| &nbsp;&nbsp;&nbsp;Rise | 211 | 211 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated total | $8277 | $8339 |

---

No single Brand Partner or customer accounted for 10% or more of net sales for the periods presented. The table below summarizes the approximate percentage of total product revenue for the Company's Core Nutritional, Hiya, and Rise reportable segments, that has been contributed by the Company's Core Nutritional, foods, and personal care and skincare products for the periods indicated.

---

| | | |
|:---|:---|:---|
| | **Three months ended** | **Three months ended** |
| | **April 4,<br>2026** | **March 29,<br>2025** |
| Core Nutritional: |  |  |
| &nbsp;&nbsp;USANA® Nutritionals | 71% | 75% |
| &nbsp;&nbsp;USANA Foods<sup>(1)</sup> | 6% | 5% |
| &nbsp;&nbsp;Personal care and skincare | 5% | 5% |
| Hiya | 13% | 14% |
| Rise | 5% | 1% |

---

**______________________________**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup>Includes the Company's Active Nutrition line.

------

<u>[**Table of Contents**](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(in thousands, except per share data)**

**(unaudited)**

*Selected Financial Information*

Financial information, presented by geographic region is listed below:

---

| | | |
|:---|:---|:---|
| | **Three months ended** | **Three months ended** |
| | **April 4,<br>2026** | **March 29,<br>2025** |
| Net sales to external customers: |  |  |
| &nbsp;&nbsp;Asia Pacific |  |  |
| &nbsp;&nbsp;&nbsp;Greater China | $123334 | $118746 |
| &nbsp;&nbsp;&nbsp;Southeast Asia Pacific | 30663 | 35720 |
| &nbsp;&nbsp;&nbsp;North Asia | 15352 | 18941 |
| &nbsp;&nbsp;&nbsp;&nbsp;Asia Pacific total | 169349 | 173407 |
| &nbsp;&nbsp;Americas and Europe <sup>(1)</sup> | 80869 | 76132 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated total | $250218 | $249539 |

---

**______________________________**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup>Includes results of the Hiya and Rise segments.

The following table provides further information on markets representing ten percent or more of consolidated net sales and long-lived assets (excluding intangible assets), respectively:

---

| | | |
|:---|:---|:---|
| | **Three months ended** | **Three months ended** |
| | **April 4,<br>2026** | **March 29,<br>2025** |
| Net sales: |  |  |
| &nbsp;&nbsp;China | $112510 | $107690 |
| &nbsp;&nbsp;United States <sup>(1)</sup> | 63531 | 57923 |

---

**______________________________**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup>Includes results of the Hiya and Rise segments.

---

| | | |
|:---|:---|:---|
| | **As of** | **As of** |
| | **April 4,<br>2026** | **January 3,<br>2026** |
| Long-lived assets: |  |  |
| &nbsp;&nbsp;United States <sup>(1)</sup> | $77497 | $77137 |
| &nbsp;&nbsp;China | 29344 | 29556 |

---

**______________________________**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup>Includes balances of the Hiya and Rise segments.

**NOTE K – REDEEMABLE NONCONTROLLING INTEREST**

On December 23, 2024, the Company acquired a controlling financial interest in Hiya. Simultaneously, USANA and the remaining noncontrolling interest holders entered into an Amended and Restated Limited Liability Company Agreement ("LLC Agreement"). The agreement granted USANA the right to buy ("Call Right") and the noncontrolling interest holders the right to cause USANA to purchase ("Put Right") half of the remaining noncontrolling interest units beginning on April 30, 2028, and the remaining unpurchased noncontrolling interest units beginning on April 30, 2030 or, if the Put Right and Call Right have not, collectively, been exercised with respect to all noncontrolling interest units prior to the end of 2030, the period beginning on April 30th of each year after 2030. The purchase price for the noncontrolling interest units pursuant to the Call Right and Put Right is based on Hiya's Adjusted EBITDA (as defined in the LLC Agreement) for the calendar year immediately prior to the year in which such right is exercised, multiplied by the Company

------

<u>[**Table of Contents**](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(in thousands, except per share data)**

**(unaudited)**

Value Reference Amount (as defined in the LLC Agreement). The Call Right and Put Right are not mandatorily redeemable. The redemption of the noncontrolling interest is contingent upon the passage of time and within the control of the interest holders, therefore, the Company has classified the noncontrolling interest as redeemable within the mezzanine section on the condensed consolidated balance sheets.

The noncontrolling interest was recognized and measured at fair value on the acquisition date. The Company records the redeemable noncontrolling interest at the greater of: (i) the carrying value, which is adjusted each period for the noncontrolling interests' share of net earnings or loss and distributions or (ii) the redemption value. The following is a reconciliation of the changes in the redeemable noncontrolling interest for the periods indicated:

---

| | |
|:---|:---|
| | **Three months ended<br>April 4, 2026** |
| Beginning balance | $53168 |
| &nbsp;&nbsp;Net (loss) earnings attributable to redeemable noncontrolling interest | (556) |
| &nbsp;&nbsp;Distributions to redeemable noncontrolling interest | (1376) |
| Ending balance | $51236 |

---

------

<u>[Table of](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u><u>[Contents](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

**Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is designed to provide an understanding of USANA's financial condition, results of operations and cash flows by reviewing certain key indicators and measures of performance.

The MD&A is presented in six sections as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Overview

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Products

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Customers

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Non-GAAP Financial Measures

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Results of Operations

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Liquidity and Capital Resources

This discussion and analysis from management's perspective should be read in conjunction with the Unaudited condensed consolidated financial statements and Notes thereto that are contained in this quarterly report, as well as Part II, Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations of our Annual Report on Form 10-K for the year ended January 3, 2026 (<u>["2025 Form 10-K"](https://www.sec.gov/ix?doc=/Archives/edgar/data/0000896264/000089626426000021/usna-20260103.htm)</u>), filed with the SEC on March 16, 2026, and our other filings, including the Current Reports on Form 8-K, that have been filed with the SEC through the date of this report. Forward-looking statements in Part I, Item 2 may involve risks and uncertainties that could cause results to differ materially from those projected (refer to the section entitled "Cautionary Note Regarding Forward-Looking Statements and Certain Risks" on page 1 and the risk factors provided in Part II, Item 1A for discussion of these risks and uncertainties).

**Overview** 

We develop and manufacture high quality nutritional supplements, functional foods and personal care products that are sold throughout the world. Historically, we have distributed our products through the direct selling channel, because we believe it is conducive to our vision of improving the overall health and nutrition of individuals and families around the world. On December 23, 2024, we acquired a 78.85% controlling ownership interest in Hiya, a leading provider of high-quality children's health and wellness products. We believe that the addition of Hiya to our business promotes our vision and adds a diversified layer of growth in the direct-to-consumer channel. In 2022, we acquired Rise and have expanded Rise's product offering, distribution channel, and customer base over the last three years. Consequently, through our Core Nutritional business, Hiya, and Rise, we now operate and sell products through an omni-channel platform, which includes direct selling, direct-to-consumer, third-party marketplace and retail channels and organize our business into three reportable segments: Core Nutritional, Hiya, and Rise.

***Core Nutritional:*** Core Nutritional is our primary business with approximately 82% of consolidated net sales during the three months ended April 4, 2026. Our Core Nutritional customer base is primarily comprised of two types of customers: "Brand Partners" and "Preferred Customers," referred to together as "active Customers." Our Brand Partners also sell our products to retail customers. Brand Partners share in our company vision by acting as independent distributors of our products in addition to purchasing our products for their personal use. In 2023, we launched our Affiliate program in the United States, Canada, and Mexico, which offers another sales and compensation opportunity to individuals who are interested in selling USANA products. Affiliates are discussed and reported in the report as part of our Brand Partners. Preferred Customers purchase our products strictly for personal use and are not permitted to resell or to distribute the products. We only count as active Customers those Brand Partners and Preferred Customers who have purchased from us at any time during the most recent three-month period. As of April 4, 2026, we had approximately 404,000 active Customers worldwide in the Core Nutritional segment.

We have Core Nutritional operations in multiple markets, with sales and expenses being generated and incurred in multiple currencies. Our reported U.S. dollar sales and earnings can be significantly affected by fluctuations in currency exchange rates. In general, our operating results are affected positively by a weakening of the U.S. dollar and negatively by a strengthening of the U.S. dollar. During the three months ended April 4, 2026, net sales outside of the United States represented 91.3% of Core Nutritional net sales. In our net sales discussions that follow, we approximate the impact of currency fluctuations on net sales by translating current year sales at the average exchange rates in effect during the comparable periods of the prior year.

------

<u>[Table of](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u><u>[Contents](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

***Hiya:*** Hiya operates and sells products to customers in the United States, Canada, and the United Kingdom. Hiya's customers purchase Hiya products for personal use primarily through a subscription model, which is intended to provide a steady, predictable income stream for Hiya. The ongoing nature of subscriptions fosters stronger relationships with customers by making it easier for them to receive products regularly, which we believe leads to retention and loyalty. Hiya's subscription model also provides important data on customer preferences and behaviors, which enables personalized offerings, efficient marketing and data-driven innovation insights. We evaluate Hiya's customer counts and behavior through their monthly subscribers and only count as "active Monthly Subscribers" those Hiya customers who have purchased from Hiya at any time during the most recent month. Hiya expanded distribution into retail during the first quarter of 2026.

***Rise:*** Rise manufactures and sells high-quality protein bars, powdered drinks, and clear protein drinks that are formulated to help customers achieve their health goals through clean and simple ingredients. Rise's revenue is generated primarily from sales to large national retailers and club retailers.

The following tables summarize operating results as a percentage of net sales for the current and prior-year periods, as indicated:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended** | **Three months ended** | **Three months ended** | **Three months ended** | **Three months ended** | **Three months ended** | **Three months ended** | **Three months ended** |
| | **April 4, 2026** | **April 4, 2026** | **April 4, 2026** | **April 4, 2026** | **March 29, 2025** | **March 29, 2025** | **March 29, 2025** | **March 29, 2025** |
| | **Core Nutritional** | **Hiya** | **Rise** | **Consolidated** | **Core Nutritional** | **Hiya** | **Rise** | **Consolidated** |
| Net sales | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of sales | 18.0% | 31.1% | 92.9% | 23.8% | 17.7% | 38.0% | 65.1% | 21.0% |
| &nbsp;&nbsp;Gross profit | 82.0% | 68.9% | 7.1% | 76.2% | 82.3% | 62.0% | 34.9% | 79.0% |
| Operating expenses: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Brand Partner incentives | 43.4% | —% | —% | 35.4% | 42.7% | —% | —% | 36.1% |
| &nbsp;&nbsp;Selling, general and administrative | 29.7% | 77.0% | 20.0% | 35.3% | 31.6% | 63.4% | 79.2% | 36.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 73.1% | 77.0% | 20.0% | 70.7% | 74.3% | 63.4% | 79.2% | 72.7% |
| Earnings (loss) from operations | 8.9% | (8.1%) | (12.9%) | 5.5% | 8.0% | (1.4%) | (44.3%) | 6.3% |
| Amortization of acquired intangible assets | —% | 13.9% | 1.5% | 1.9% | —% | 12.0% | 13.0% | 1.9% |

---

For more information relating to our reportable segments, see <u>[Note J](#i07b26d4eeded49c69f3a6bfc811b20be_67)</u> to our condensed consolidated financial statements.

------

<u>[Table of](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u><u>[Contents](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

**Products** 

The following table summarizes the approximate percentage of total product revenue for the Core Nutritional segment that has been contributed by major product lines and our top-selling products for the current and prior-year periods, as indicated:

---

| | | |
|:---|:---|:---|
| | **Three months ended** | **Three months ended** |
| | **April 4, 2026** | **March 29, 2025** |
| **<u>Product line</u>** | | |
| USANA® Nutritionals |  |  |
| &nbsp;&nbsp;Optimizers | 72% | 72% |
| &nbsp;&nbsp;Essentials/CellSentials<sup>(1)</sup> | 14% | 16% |
| USANA Foods<sup>(2)</sup> | 7% | 6% |
| Personal care and Skincare | 6% | 5% |
| All other | 1% | 1% |
| **<u>Key product</u>** |  |  |
| USANA® Essentials/CellSentials | 8% | 9% |
| Proflavanol® | 7% | 9% |
| Probiotic | 6% | 7% |

---

**______________________________**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup>Represents a product line consisting of multiple products, as opposed to the actual USANA® Essentials / CellSentials product.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(2)</sup>Includes our Active Nutrition line.

The following table summarizes the approximate percentage of total product revenue for our Hiya segment that has been contributed by major product lines for the current and prior-year periods, as indicated:

---

| | | |
|:---|:---|:---|
| | **Three months ended** | **Three months ended** |
|<br>**Product line** | **April 4, 2026** | **March 29, 2025** |
| Kids Daily Multivitamin | 55% | 52% |
| Kids Daily Probiotic | 14% | 14% |
| Kids Daily Greens and Superfoods | 12% | 17% |
| Kids Bedtime Essentials | 11% | 10% |
| Kids Daily Iron | 4% | 4% |
| Kids Daily Hydration | 2% | —% |
| Kids Daily Immune | 1% | 3% |
| Kids Daily Fiber+ | 1% | —% |

---

The following table summarizes the approximate percentage of total product revenue for our Rise segment that has been contributed by major product lines for the current and prior-year periods, as indicated:

---

| | | |
|:---|:---|:---|
| | **Three months ended** | **Three months ended** |
|<br>**Product line** | **April 4, 2026** | **March 29, 2025** |
| Protein Pop <sup>(1)</sup> | 75% | —% |
| Bars | 24% | 89% |
| Powders | 1% | 11% |

---

**______________________________**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup>Protein Pop was launched in the third quarter of 2025.

------

<u>[Table of](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u><u>[Contents](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

**Customers** 

***Core Nutritional***

Because we primarily sell our products to a customer base of independent Brand Partners and Preferred Customers, we increase our sales by increasing the number of our active Customers, the amount they spend on average, or both. Our primary focus continues to be increasing the number of active Customers. We believe this focus is consistent with our vision of improving the overall health and nutrition of individuals and families around the world. Increases or decreases in product sales are typically the result of variations in the volume of product sold relating to fluctuations in the number of active Customers purchasing our products. The number of active Customers is, therefore, used by management as a key non-financial indicator to evaluate our operational performance.

Sales to Brand Partners accounted for approximately 50% of Core Nutritional segment sales during the three months ended April 4, 2026, with the remainder of our sales generated from Preferred Customers. As of April 4, 2026, Brand Partners and Preferred Customers represented approximately 41% and 59%, respectively, of the total active Customer base for the quarter in the Core Nutritional segment. The table below summarizes the changes in our active Customer base for the Core Nutritional segment by geographic region, rounded to the nearest thousand as of the dates indicated:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Total active customers by region** | **Total active customers by region** | **Total active customers by region** | **Total active customers by region** | **Change from prior year** | **Percent change** |
| | **As of <br>April 4, 2026** | **As of <br>April 4, 2026** | **As of <br>March 29, 2025** | **As of <br>March 29, 2025** | **Change from prior year** | **Percent change** |
| Asia Pacific: |  |  |  |  |  |  |
| &nbsp;&nbsp;Greater China | 235000 | 58.2% | 254000 | 55.3% | (19000) | (7.5%) |
| &nbsp;&nbsp;Southeast Asia Pacific | 59000 | 14.6% | 75000 | 16.4% | (16000) | (21.3%) |
| &nbsp;&nbsp;North Asia | 32000 | 7.9% | 45000 | 9.8% | (13000) | (28.9%) |
| Asia Pacific total | 326000 | 80.7% | 374000 | 81.5% | (48000) | (12.8%) |
| Americas and Europe | 78000 | 19.3% | 85000 | 18.5% | (7000) | (8.2%) |
|  | 404000 | 100.0% | 459000 | 100.0% | (55000) | (12.0%) |

---

***Hiya***

Hiya's active Monthly Subscribers are comprised of two types: first-time customers and recurring customers. First-time customers are viewed as an investment as the customer is provided a discount, and shipping costs are higher due to the inclusion of a refillable glass bottle. Additionally, as a direct-to-consumer company, customer acquisition is heavily influenced by the level of marketing spend. Recurring customers are not provided the same discount, and shipping costs are lower on refill orders. Both gross margins as well as operating margins improve with recurring customer orders, therefore, profitability margins are affected by sales mix between these two types of customers. As of April 4, 2026 and March 29, 2025, Hiya had approximately 186,000 and 224,000 active Monthly Subscribers, respectively.

***Rise***

Rise sells its products primarily to large national retailers and club retailers throughout the United States. Rise does not operate under long-term supply agreements with any of its retail customers. Instead, sales are generally made pursuant to purchase orders. As a result, our revenue in any given period is dependent on ordering patterns and inventory management decisions made by our retail customers, which can be difficult to predict and may vary significantly from period to period. Rise offers trade promotions, discounts, spoilage, and other retailer deductions, which are recorded as reductions to gross revenue.

------

<u>[Table of](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u><u>[Contents](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

**Non-GAAP Financial Measures** 

We believe that presentation of certain non-GAAP financial information is meaningful and useful in understanding the activities and business metrics of our operations. Management believes these measures reflect an additional way of viewing aspects of our business that, when viewed with our U.S. GAAP results, provide a more complete understanding of factors and trends affecting our business. This non-GAAP financial information may be determined or calculated differently by other companies, limiting the usefulness of those measures for comparative purposes. We provide such non-GAAP financial information for informational purposes only. Readers should consider the information in addition but not instead of or superior to, our condensed consolidated financial statements prepared in accordance with U.S. GAAP, accompanying this report.

In analyzing business trends and performance, management uses "constant currency" net sales, "local currency" net sales, and other currency-related financial information terms to discuss our financial results in a way we believe is helpful in understanding the impact of fluctuations in foreign-currency exchange rates and facilitating period-to-period comparisons of results of operations and providing investors an additional perspective on trends and underlying business results. Changes in our reported revenue and profits in this report include the impacts of changes in foreign currency exchange rates. As additional information to the reader, we provide constant currency assessments in the tables and the narrative information in this MD&A to remove or quantify the impact of the fluctuation in foreign exchange rates and utilize constant currency results in our analysis of performance. Our constant currency financial results are calculated by translating the current period's financial results at the same average exchange rates in effect during the applicable prior-year period and then comparing this amount to the prior-year period's financial results.

**Results of Operations**

*Summary of Financial Results*

Net sales for the first quarter of 2026 increased 0.3% to $250.2 million, an increase of $0.7 million, compared with the prior-year quarter. The modest increase in sales is the result of incremental net sales of $12.0 million for Rise, partially offset by a decline in both the Core Nutritional and Hiya segments of $6.4 million and $4.9 million, respectively. Additionally, favorable changes in currency exchange rates positively impacted net sales by an estimated $8.1 million in the current-year quarter.

Net earnings attributable to USANA for the first quarter of 2026 were $7.5 million, a decrease of 20.1% compared with $9.4 million during the prior-year quarter. The change is primarily attributable to a lower operating margin and a higher effective tax rate in the current-year quarter.

------

<u>[Table of](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u><u>[Contents](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

**Three months ended April 4, 2026 and March 29, 2025**

*Net Sales*

The following table summarizes the changes in net sales by segment for the fiscal quarters ended as of the dates indicated:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Net sales by region<br>(in thousands)** | **Net sales by region<br>(in thousands)** | **Net sales by region<br>(in thousands)** | **Net sales by region<br>(in thousands)** | **Change from prior year** | **Percent change** | **Currency impact on<br>sales** | **Percent change excluding currency impact** |
| | **Three months ended** | **Three months ended** | **Three months ended** | **Three months ended** | **Change from prior year** | **Percent change** | **Currency impact on<br>sales** | **Percent change excluding currency impact** |
| | **April 04, 2026** | **April 04, 2026** | **March 29, 2025** | **March 29, 2025** | **Change from prior year** | **Percent change** | **Currency impact on<br>sales** | **Percent change excluding currency impact** |
| Core Nutritional: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Asia Pacific |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Greater China | $123334 | 49.3% | $118746 | 47.6% | $4588 | 3.9% | $4986 | (0.3%) |
| &nbsp;&nbsp;&nbsp;&nbsp;Southeast Asia Pacific | 30663 | 12.3% | 35720 | 14.3% | (5057) | (14.2%) | 1942 | (19.6%) |
| &nbsp;&nbsp;&nbsp;&nbsp;North Asia | 15352 | 6.1% | 18941 | 7.6% | (3589) | (18.9%) | (160) | (18.1%) |
| &nbsp;&nbsp;Asia Pacific total | 169349 | 67.7% | 173407 | 69.5% | (4058) | (2.3%) | 6768 | (6.2%) |
| &nbsp;&nbsp;Americas and Europe | 35050 | 14.0% | 37417 | 15.0% | (2367) | (6.3%) | 1323 | (9.9%) |
| Core Nutritional total | 204399 | 81.7% | 210824 | 84.5% | (6425) | (3.0%) | 8091 | (6.9%) |
| Hiya | 32150 | 12.8% | 37089 | 14.9% | (4939) | (13.3%) |  | (13.3%) |
| Rise | 13669 | 5.5% | 1626 | 0.6% | 12043 | 740.7% |  | 740.7% |
| Consolidated total | $250218 | 100.0% | $249539 | 100.0% | $679 | 0.3% | $8091 | (3.0%) |

---

*<u>Core Nutritional Net Sales</u>*

Net sales in the Core Nutritional segment for the three-month period ended April 4, 2026 were $204.4 million, down 3.0% when compared to the corresponding period of 2025. On a constant currency basis, net sales in the Core Nutritional segment declined 6.9%. The decrease in Core Nutritional net sales was mainly due to a 12.0% decrease in active Customers, partially offset by a 5.6% increase in average spend per active Customer.

<u>Asia Pacific:</u> Net sales declined 2.3%, or 6.2% on a constant currency basis, in this region during the current-year quarter. Active Customers in this region declined 12.8% year-over-year, partially offset by an increase in average spend per active Customer. The net sales decline reflects a challenging economic and operating environment.

The following table summarizes changes in local currency net sales, active Customer counts, and average spend per active Customer for the markets primarily contributing to the decline in net sales within the Asia Pacific region:

---

| | | | |
|:---|:---|:---|:---|
| **Market** | **Local currency net sales** | **Active Customers** | **Average spend per active Customer** |
| &nbsp;&nbsp;South Korea | (18.5%) | (29.5%) | 15.9% |
| &nbsp;&nbsp;Malaysia | (24.1%) | (36.0%) | 18.6% |
| &nbsp;&nbsp;The Philippines | (23.5%) | (26.3%) | 3.8% |
| &nbsp;&nbsp;Singapore | (25.9%) | (22.2%) | (4.7%) |
| &nbsp;&nbsp;China | (0.4%) | (7.6%) | 7.8% |

---

------

<u>[Table of](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u><u>[Contents](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

<u>Americas and Europe:</u> Net sales declined 6.3%, or 9.9% on a constant currency basis, in this region during the current-year quarter. Active Customers in this region declined 8.2% year-over-year and average spend per active Customer decreased 1.1% year-over-year. Year-over-year results in this region reflect a continued challenging environment to attract new customers.

The following table summarizes changes in local currency net sales, active Customer counts, and average spend per active Customer for the markets primarily contributing to the decline in net sales within the Americas and Europe region:

---

| | | | |
|:---|:---|:---|:---|
| **Market** | **Local currency net sales** | **Active Customers** | **Average spend per active Customer** |
| &nbsp;&nbsp;United States | (6.0%) | (2.9%) | (3.2%) |
| &nbsp;&nbsp;Canada | (9.7%) | (6.9%) | (2.9%) |
| &nbsp;&nbsp;Mexico | (10.9%) | (7.1%) | (4.1%) |

---

*<u>Hiya Net Sales</u>*

Net sales in the Hiya segment for the three-month period ended April 4, 2026 were $32.2 million, down 13.3% when compared to the corresponding period of 2025. The decrease was primarily the result of a lower customer base and a decrease in customer acquisitions.

*<u>Rise Net Sales</u>*

Net sales in the Rise segment for the three-month period ended April 4, 2026 were $13.7 million, up 740.7% when compared to the corresponding period of 2025. The increase was primarily the result of the launch of Protein Pop in large national retailers and club retailers.

*Gross Profit*

Consolidated gross profit decreased 280 basis points to 76.2% of net sales, down from 79.0% in the prior-year quarter. The decrease in gross profit is largely attributed to an approximate 370 basis point unfavorable impact on consolidated results from incremental net sales for Rise, which carry lower gross margins relative to the Core Nutritional segment. Gross margins were also down for the Core Nutritional segment by 100 basis points due to production inefficiencies driven by lower production levels, as well as an increase in material costs. The overall decrease was partially offset by a positive contribution to the consolidated gross margin of 190 basis points from our Hiya segment, resulting primarily from a favorable shift in sales mix, and higher costs in the prior-year quarter related to the recognition of a step-up in basis of acquired inventory.

*Brand Partner Incentives*

Brand Partner incentives expense is incurred only in the Core Nutritional segment. Brand Partner incentives on a consolidated basis decreased 70 basis points to 35.4% of consolidated net sales, down from 36.1% in the prior-year quarter. This decrease can be attributed to the increase in net sales within our Rise segment where no Brand Partner incentives are incurred. For our Core Nutritional segment, Brand Partner incentives increased 70 basis points to 43.4% of segment net sales, up from 42.7% in the prior-year quarter. The relative increase was primarily driven by an unfavorable shift in market mix to a higher payout, an increase in incentive promotions, partially offset by lower accruals for incentive trips and events, and benefits from price increases.

*Selling, General and Administrative Expenses*

Selling, general and administrative expenses decreased $3.2 million in absolute terms during the current-year quarter, or 130 basis points relative to net sales. The overall decrease reflects an approximate 165 basis point favorable impact on consolidated results from the Core Nutritional segment attributed to cost realignment strategies implemented in the fourth quarter of fiscal year 2025, which were primarily related to employee costs and facility lease expense. Rise impacted consolidated selling, general and administrative favorably by 115 basis points as a result of leverage gained on higher net sales. However, Hiya negatively impacted consolidated selling, general and administrative expenses by 150 basis points due to higher spending on lower sales.

------

<u>[Table of](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u><u>[Contents](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

*Income Taxes*

The year-to-date effective tax rate increased to 55.0% from the 44.5% reported in the comparable period of fiscal 2025. The higher effective tax rate is due to lower consolidated earnings projections and an unfavorable change in mix of taxable income by market. Earnings before income taxes for the current-year quarter totaled $15.5 million with income tax expense of $8.5 million, or 55% of pretax income.

*Diluted Earnings per Share Attributable to USANA*

Diluted earnings per share attributable to USANA decreased to $0.41 as compared to $0.49 reported in the prior-year quarter primarily as a result of the substantially higher income tax provision as well as lower earnings from operations in the current-year quarter.

**Liquidity and Capital Resources**

We have historically met our working capital and capital expenditure requirements by using net cash flow from operations and by drawing on our line of credit. Our principal source of liquidity is our operating cash flow. Although we are required to maintain cash deposits with banks in certain of our markets, there are currently no material restrictions on our ability to transfer and remit funds among our international markets. In China, however, our compliance with Chinese accounting and tax regulations promulgated by the State Administration of Foreign Exchange ("SAFE") results in transfer and remittance of our profits and dividends from China to the United States on a delayed basis. If SAFE or other Chinese regulators introduce new regulations or change existing regulations which allow foreign investors to remit profits and dividends earned in China to other countries, our ability to remit profits or pay dividends from China to the United States may be limited in the future.

We believe our current liquidity, through cash flow from operations along with our line of credit, is adequate to meet our cash requirements and sustain our operations. Maintaining a capital structure that emphasizes sufficient liquidity and adaptability in the prevailing economic climate is our top priority. We actively assess potential acquisition opportunities and investments in complementary ventures. While we continuously aim to preserve ample liquidity and ensure business continuity amid uncertainties, we also explore initiatives such as stock repurchases. These strategic decisions have the potential to impact our liquidity and the ability to navigate these challenging times effectively.

*Cash and Cash Equivalents*

Cash and cash equivalents increased to $162.8 million as of April 4, 2026, from $158.4 million as of January 3, 2026. Cash flow provided by operating activities was $9.8 million, offset by cash used in financing activities of $3.6 million, and cash used in investing activities of $2.6 million. Additionally, favorable changes in currency exchange rates have impacted cash and cash equivalents, and restricted cash by $0.9 million.

The table below presents concentrations of cash and cash equivalents by market for the periods indicated:

---

| | | |
|:---|:---|:---|
| | **Cash and cash equivalents<br>(in millions)** | **Cash and cash equivalents<br>(in millions)** |
| | **As of <br>April 4, 2026** | **As of <br>January 3, 2026** |
| United States | $16.1 | $28.6 |
| China | 111.0 | 89.3 |
| All other markets | 35.7 | 40.5 |
| &nbsp;&nbsp;&nbsp;Total cash and cash equivalents | $162.8 | $158.4 |

---

*Cash Flows Provided by Operations*

As discussed above, our principal source of liquidity comes from our net cash flow from operations.

Net cash flow provided by operating activities was $9.8 million for the first three months of 2026. Net earnings combined with adjustments of non-cash items and a decrease in inventory purchases contributed positively to our net cash flow provided by operating activities, partially offset by an increase in trade accounts receivable, reflecting higher sales to

------

<u>[Table of](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u><u>[Contents](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

retail customers in the Rise segment, as well as cash used to pay the 2025 annual employee bonus and accrued Brand Partner incentives.

Net cash flow provided by operating activities was $15.5 million for the first three months of 2025. Net earnings combined with adjustments of non-cash items contributed positively to our net cash flow provided by operating activities, partially offset by cash used to pay the 2024 annual employee bonus and accrued Brand Partner incentives and the purchase of inventories.

*Line of Credit* 

Information with respect to our line of credit may be found in <u>[Note F](#i07b26d4eeded49c69f3a6bfc811b20be_55)</u> to the condensed consolidated financial statements included in Item 1 of Part I of this report.

*Share Repurchases*

Information with respect to share repurchases may be found in <u>[Note I](#i07b26d4eeded49c69f3a6bfc811b20be_64)</u> to the condensed consolidated financial statements included in Item 1 of Part I of this report.

*Summary*

We believe our current cash balances, future cash provided by operations, and amounts available under our line of credit will be sufficient to cover our operating and capital needs in the ordinary course of business for the foreseeable future. If we experience an adverse operating environment or unanticipated and unusual capital expenditure requirements, additional financing may be required. No assurance can be given, however, that additional financing, if required, would be available to us at all or on favorable terms. We might also require or seek additional financing for the purpose of expanding into new markets, growing our existing markets, mergers and acquisitions, or for other reasons. Such financing may include the use of debt or the sale of additional equity securities. Any financing which involves the sale of equity securities or instruments that are convertible into equity securities could result in immediate and possibly significant dilution to our existing shareholders.

***Critical Accounting Policies***

There were no changes during the quarter to our critical accounting policies as disclosed in our 2025 Form 10-K. Our significant accounting policies are disclosed in Note A to our Consolidated Financial Statements filed with our 2025 Form 10-K.

**Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

We have no material changes to the disclosures on this matter made in our 2025 Form 10-K. For a discussion of our exposure to market risk, refer to our market risk disclosures set forth in the section entitled "Quantitative and Qualitative Disclosures About Market Risk" in the <u>[2025 Form 10-K.](https://www.sec.gov/ix?doc=/Archives/edgar/data/0000896264/000089626426000021/usna-20260103.htm)</u>

**Item 4. CONTROLS AND PROCEDURES** 

**Evaluation of Disclosure Controls and Procedures**

We maintain disclosure controls and procedures that are designed to ensure that information that is required to be disclosed in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods that are specified in the SEC's rules and forms and that such information is accumulated and communicated to management, including our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), as appropriate, to allow timely decisions regarding any required disclosure. In designing and evaluating these disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

As of the end of the period covered by this report, our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). Based on this evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures were effective to provide reasonable assurance as of April 4, 2026.

------

<u>[Table of](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u><u>[Contents](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

**Changes in Internal Control Over Financial Reporting**

During the quarter, the Company integrated Rise into its enterprise resource planning system. As a result, the Company implemented changes to business processes and related internal controls over financial reporting related to Rise. We believe we maintained appropriate internal control over financial reporting during the integration. These changes have been and will continue to be subject to our evaluation of the design and operating effectiveness of our internal control over financial reporting. Other than the changes related to Rise, there were no changes in our internal control over financial reporting during the fiscal quarter ended April 4, 2026, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

------

<u>[Table of](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u><u>[Contents](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

**PART II. OTHER INFORMATION**

**Item 1. LEGAL PROCEEDINGS**

We are a party to litigation and other proceedings that arise in the ordinary course of conducting business, including matters involving our products, intellectual property, supplier relationships, distributors, competitor relationships, employees, and other matters.

Information with respect to our legal proceedings may be found in <u>[Note G](#i07b26d4eeded49c69f3a6bfc811b20be_58)</u> to the condensed consolidated financial statements included in Item 1 Part I of this report.

**Item 1A. RISK FACTORS**

Our business, results of operations, and financial condition are subject to various risks. Our material risk factors are disclosed in Part I, Item 1A of our <u>[2025 Form 10-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/0000896264/000089626426000021/usna-20260103.htm)</u>. The risk factors identified in our 2025 Form 10-K have not changed in any material respect.

**Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

*(c) Purchases of Equity Securities by the Issuer and Affiliated Purchasers*

Our share repurchase plan has been ongoing since the fourth quarter of 2000, with the Board of Directors periodically approving additional dollar amounts for share repurchases under the plan. At April 4, 2026, the authorized amount available for repurchases under the plan was $34.0 million.

Repurchases are made from time to time at management's discretion in accordance with applicable federal securities laws. Repurchases may occur through open market purchases, pursuant to a Rule 10b5-1 trading plan, or in other transactions as permitted by the rules of the SEC. There is no requirement for future share repurchases, and there is no expiration date of the repurchase plan.

During the three months ended April 4, 2026, we did not make any purchases of our common stock under our share repurchase plan.

**Item 5. OTHER INFORMATION**

During the three months ended April 4, 2026, none of our directors or officers informed us of the adoption, modification or termination of a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as those terms are defined in Regulation S-K, Item 408.

------

<u>[Table of](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u><u>[Contents](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

**Item 6. EXHIBITS** 

Exhibits marked with an asterisk (\*) are filed herewith.

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 31.1 | <u>[\*Certification of Principal Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002](usna-20260404xex311.htm)</u> |
| 31.2 | <u>[\*Certification of Principal Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002](usna-20260404xex312.htm)</u> |
| 32.1 | <u>[\*Certification of Principal Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350](usna-20260404xex321.htm)</u> |
| 32.2 | <u>[\*Certification of Principal Financial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350](usna-20260404xex322.htm)</u> |
| 101.INS | Inline XBRL Instance Document |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data file (formatted as Inline XBRL and contained in Exhibit 101) |

---

------

<u>[Table of](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u><u>[Contents](#i07b26d4eeded49c69f3a6bfc811b20be_7)</u>

 **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
| Date: May 12, 2026 | USANA HEALTH SCIENCES, INC. |
| | /s/ G. Douglas Hekking |
| | G. Douglas Hekking |
| | Chief Financial Officer<br>(Principal Financial Officer) |

---

## Exhibit 31.1

**EXHIBIT 31.1**

**CHIEF EXECUTIVE OFFICER CERTIFICATION** 

I, Kevin G. Guest, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Quarterly Report on Form 10-Q of USANA Health Sciences, Inc. (the "Registrant");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: May 12, 2026 | /s/ Kevin G. Guest |
|  | Kevin G. Guest |
|  | Chief Executive Officer<br>(Principal Executive Officer) |

---

## Exhibit 31.2

**EXHIBIT 31.2**

**CHIEF FINANCIAL OFFICER CERTIFICATION** 

I, G. Douglas Hekking, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Quarterly Report on Form 10-Q of USANA Health Sciences, Inc. (the "Registrant");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: May 12, 2026 | /s/ G. Douglas Hekking |
|  | G. Douglas Hekking |
| | Chief Financial Officer<br>(Principal Accounting and Financial Officer) |

---

## Exhibit 32.1

**EXHIBIT 32.1**

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,** 

**AS ADOPTED PURSUANT TO SECTION 906** 

**OF THE SARBANES-OXLEY ACT OF 2002**

The undersigned hereby certifies that the Quarterly Report on Form 10-Q of USANA Health Sciences, Inc. for the period ended April 4, 2026 as filed May 12, 2026 with the Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or 15(d) of The Securities Exchange Act of 1934 (15 U.S.C. 78m) and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of USANA Health Sciences, Inc.

---

| | |
|:---|:---|
| Date: May 12, 2026 | /s/ Kevin G. Guest |
| | Kevin G. Guest |
| | Chief Executive Officer<br>(Principal Executive Officer) |

---

## Exhibit 32.2

**EXHIBIT 32.2**

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906** 

**OF THE SARBANES-OXLEY ACT OF 2002**

The undersigned hereby certifies that the Quarterly Report on Form 10-Q of USANA Health Sciences, Inc. for the period ended April 4, 2026 as filed May 12, 2026 with the Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or 15(d) of The Securities Exchange Act of 1934 (15 U.S.C. 78m) and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of USANA Health Sciences, Inc.

---

| | |
|:---|:---|
| Date: May 12, 2026 | /s/ G. Douglas Hekking |
|  | G. Douglas Hekking |
|  | Chief Financial Officer<br>(Principal Accounting and Financial Officer) |

---

<br>